PHASE I DOSE-ESCALATION STUDY OF VORINOSTAT COMBINED WITH GEMCITABINE AND PLATINUM AGENTS IN ADVANCED NON-SMALL-CELL LUNG CANCER

被引：0
|
作者：
Descourt, R. [1 ]
Zalcman, G. [2 ]
Moro-Sibilot, D. [3 ,4 ]
Tredaniel, J. [5 ]
Misset, J. [5 ]
Gachard, E. [6 ]
Garcia-Vargas, J. [7 ]
Reiser, D. [8 ]
Roben, E. [8 ]
Rizvi, S. [8 ]
机构：
[1] Inst Cancerol & Hematol, Chu Morvan, Brest, France
[2] CHU Grenoble, PMAC Clin Pneumol, Grenoble, France
[3] Serv Pneumol, Caen, France
[4] Ctr Rech Clin, Caen, France
[5] Hosp Saint Louis, Paris, France
[6] Merck Sharp & Dohme Ltd, Paris, France
[7] Merck & Co Inc, Oncol Clin Res, Upper Gwynedd, PA USA
[8] Merck Res Labs, Upper Gwynedd, PA USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：111 / 111
页数：1
相关论文
共 50 条
  • [1] Vorinostat in combination with gemcitabine plus platinum in patients with advanced non-small-cell lung cancer: A phase I, dose-escalation study
    Misset, J.
    Tredaniel, J.
    Descourt, R.
    Morot-Sibilot, D.
    Zalcman, G.
    Gachard, E.
    Garcia-Vargas, J.
    Rizvi, S.
    Reiser, D.
    Roben, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Phase I dose-escalation study of vorinostat in combination with gemcitabine and cisplatinum in patients with advanced non-small-cell lung cancer (NSCLC)
    Teixeira, L.
    Descourt, R.
    Moro-Sibilot, D.
    Misset, J. L.
    Gachard, E.
    Rizvi, S.
    Roben, E.
    Zalcman, G.
    EJC SUPPLEMENTS, 2009, 7 (02): : 554 - 554
  • [3] Vorinostat in combination with gemcitabine and cisplatinum in patients with advanced non-small cell lung cancer (NSCLC): A Phase I dose-escalation study
    Tredaniel, J.
    Descourt, R.
    Moro-Sibilot, D.
    Misset, J.
    Gachard, E.
    Garcia-Vargas, J.
    Roben, E.
    Zalcman, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study
    Reck, Martin
    Frickhofen, Norbert
    Cedres, Susana
    Gatzemeier, Ulrich
    Heigener, David
    Fuhr, Heinz-Georg
    Thall, Aron
    Lanzalone, Silvana
    Stephenson, Patricia
    Ruiz-Garcia, Ana
    Chao, Richard
    Felip, Enriqueta
    LUNG CANCER, 2010, 70 (02) : 180 - 187
  • [5] A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer
    Kaira, Kyoichi
    Sunaga, Noriaki
    Yanagitani, Noriko
    Imai, Hisao
    Utsugi, Mitsuyoshi
    Shimizu, Yasuo
    Iijima, Hironobu
    Tomizawa, Yoshio
    Hisada, Takeshi
    Ishizuka, Tamotsu
    Saito, Ryusei
    Mori, Masatomo
    ANTI-CANCER DRUGS, 2007, 18 (04) : 471 - 476
  • [6] A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer
    Kotsakis, Athanasios
    Agelaki, Sophia
    Vardakis, Nikolaos
    Stathopoulos, George
    Vamvakas, Lambros
    Kalykaki, Antonia
    Kentepozidis, Nikolaos
    Kontopodis, Emmanouel
    Sfakiotaki, Georgia
    Mavroudis, Dimitris
    Georgoulias, Vassilis
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (02) : 415 - 422
  • [7] A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer
    Athanasios Kotsakis
    Sophia Agelaki
    Nikolaos Vardakis
    George Stathopoulos
    Lambros Vamvakas
    Antonia Kalykaki
    Nikolaos Kentepozidis
    Emmanouel Kontopodis
    Georgia Sfakiotaki
    Dimitris Mavroudis
    Vassilis Georgoulias
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 415 - 422
  • [8] Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: Usefulness of mathematic modeling to determine maximum-tolerable dose
    Shepherd, FA
    Burkes, R
    Cormier, Y
    Crump, M
    Feld, R
    Strack, T
    Schulz, M
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) : 1656 - 1662
  • [9] Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer
    Koji Takeda
    Shunichi Negoro
    Nobuhide Takifuji
    Takashi Nitta
    Naruo Yoshimura
    Kazuhiko Terakawa
    Masahiro Fukuoka
    Cancer Chemotherapy and Pharmacology, 2001, 48 : 104 - 108
  • [10] Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer
    Takeda, K
    Negoro, S
    Takifuji, N
    Nitta, T
    Yoshimura, N
    Terakawa, K
    Fukuoka, M
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (02) : 104 - 108
12345